Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 3

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2

Conditions

Oligodendroglioma 1Healthy Adult Participants 1Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Interventional × vorasidenib × Clear all
NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Servier

Phase 1 Active not recruiting
60 enrolled
CNS

Astrocytoma, Oligodendroglioma

NCT07235748 2026-02-17

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Servier

Phase 1 Completed
28 enrolled

Healthy Adult Participants

NCT05609994 2025-07-18

ViCToRy

Duke University

Phase 1 Recruiting
48 enrolled
CNS

Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡